4.7 Article

Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice

Journal

MOLECULAR THERAPY
Volume 28, Issue 10, Pages 2203-2219

Publisher

CELL PRESS
DOI: 10.1016/j.ymthe.2020.06.026

Keywords

-

Funding

  1. Rohto Pharmaceutical
  2. Kowa Pharmaceutical
  3. Japan Society for the Promotion of Science [19K08978, 19K08980, 19K09023, 18H02863, 18K16229]
  4. CREST, JST
  5. Uehara Memorial Life Science Foundation
  6. Osaka University Innovation Bridge grant
  7. Grants-in-Aid for Scientific Research [19K09023, 18K16229, 18H02863, 19K08978, 19K08980] Funding Source: KAKEN

Ask authors/readers for more resources

Mesenchymal stem/stromal cells (MSCs) are cultured adult stem cells that originally reside in virtually all tissues, and the gain of MSCs by transplantation has become the leading form of cell therapy in various diseases. However, there is limited knowledge on the alteration of its efficacy by factors in recipients. Here, we report that the cardioprotective properties of intravenously injected MSCs in a mouse model of pressure-overload heart failure largely depend on circulating adiponectin, an adipocyte-secreted factor. The injected MSCs exert their function through exosomes, extracellular vesicles of endosome origin. Adiponectin stimulated exosome biogenesis and secretion through binding to T-cadherin, a unique glycosylphosphatidylinositol-anchored cadherin, on MSCs. A pharmacological or adenovirus-mediated genetic increase in plasma adiponectin enhanced the therapeutic efficacy of MSCs. Our findings provide novel insights into the importance of adiponectin in mesenchymal-progenitor-mediated organ protections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available